These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Florio T; Barbieri F Drug Discov Today; 2012 Oct; 17(19-20):1103-10. PubMed ID: 22704957 [TBL] [Abstract][Full Text] [Related]
23. The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness. Gao X; Jin W Cancer Lett; 2014 Oct; 353(1):25-31. PubMed ID: 25042866 [TBL] [Abstract][Full Text] [Related]
24. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200 [TBL] [Abstract][Full Text] [Related]
25. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Schonberg DL; Lubelski D; Miller TE; Rich JN Mol Aspects Med; 2014 Oct; 39():82-101. PubMed ID: 23831316 [TBL] [Abstract][Full Text] [Related]
26. Deregulated microRNAs identified in isolated glioblastoma stem cells: an overview. Chu PM; Ma HI; Chen LH; Chen MT; Huang PI; Lin SZ; Chiou SH Cell Transplant; 2013; 22(4):741-53. PubMed ID: 23127968 [TBL] [Abstract][Full Text] [Related]
27. Stem cell signature in glioblastoma: therapeutic development for a moving target. Nakano I J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368 [TBL] [Abstract][Full Text] [Related]
28. Metabolic heterogeneity and adaptability in brain tumors. Badr CE; Silver DJ; Siebzehnrubl FA; Deleyrolle LP Cell Mol Life Sci; 2020 Dec; 77(24):5101-5119. PubMed ID: 32506168 [TBL] [Abstract][Full Text] [Related]
29. MRI characteristics and histological changes in glioblastoma after gene therapy. Weber FW; Floeth FW; Reifenberger G; Felsberg J; Aulich A; Kiwit JC; Bock WJ Front Radiat Ther Oncol; 1999; 33():244-52. PubMed ID: 10549494 [No Abstract] [Full Text] [Related]
33. The Dynamics of Interactions Among Immune and Glioblastoma Cells. Eder K; Kalman B Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516 [TBL] [Abstract][Full Text] [Related]
34. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506 [TBL] [Abstract][Full Text] [Related]
35. Bisacodyl and its cytotoxic activity on human glioblastoma stem-like cells. Implication of inositol 1,4,5-triphosphate receptor dependent calcium signaling. Dong J; Aulestia FJ; Assad Kahn S; Zeniou M; Dubois LG; El-Habr EA; Daubeuf F; Tounsi N; Cheshier SH; Frossard N; Junier MP; Chneiweiss H; Néant I; Moreau M; Leclerc C; Haiech J; Kilhoffer MC Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):1018-1027. PubMed ID: 28109792 [TBL] [Abstract][Full Text] [Related]